



## Trading in Alkermes Ordinary Shares Halted Today

November 1, 2018

### -- FDA Advisory Committee to Review New Drug Application for ALKS 5461 for the Adjunctive Treatment of Major Depressive Disorder --

DUBLIN, Nov. 1, 2018 /PRNewswire/ -- [Alkermes plc](#) (Nasdaq: ALKS) today announced that Nasdaq has temporarily halted trading of the company's ordinary shares. The joint meeting of the Psychopharmacologic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee, appointed by the U.S. Food and Drug Administration (FDA), will meet today to review the company's New Drug Application (NDA) for ALKS 5461. ALKS 5461 is a once-daily, oral investigational medicine with a novel mechanism of action for the adjunctive treatment of major depressive disorder (MDD) in patients with an inadequate response to standard antidepressant therapies.

The advisory committee meeting is scheduled for 8:00 a.m. ET. The briefing materials and webcast information can be found on the FDA website at <https://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/PsychopharmacologicDrugsAdvisoryCommittee/ucm598677.htm>.

The Prescription Drug User Fee Act (PDUFA) action date for the ALKS 5461 NDA is Jan. 31, 2019.

#### **About ALKS 5461**

ALKS 5461 is a proprietary, investigational, once-daily oral medicine that acts as an opioid system modulator and represents a novel mechanism of action for the adjunctive treatment of major depressive disorder (MDD) in patients with an inadequate response to standard antidepressant therapies. ALKS 5461 is a fixed-dose combination of buprenorphine, a partial mu-opioid receptor agonist and kappa-opioid receptor antagonist, and samidorphan, a mu-opioid receptor antagonist.

#### **About MDD**

According to the *DSM-5® (Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition)*, major depressive disorder (MDD) is a condition in which patients exhibit depressive symptoms, such as a depressed mood or a loss of interest or pleasure in daily activities consistently for at least a two-week period, and demonstrate impaired social, occupational, educational or other important functioning. An estimated 16.2 million people in the U.S. suffered from MDD in 2016,<sup>1</sup> the majority of whom may not adequately respond to initial antidepressant therapy.<sup>2</sup>

#### **About Alkermes plc**

Alkermes plc is a fully integrated, global biopharmaceutical company developing innovative medicines for the treatment of central nervous system (CNS) diseases. The company has a diversified commercial product portfolio and a substantial clinical pipeline of product candidates for chronic diseases that include schizophrenia, depression, addiction and multiple sclerosis. Headquartered in Dublin, Ireland, Alkermes plc has an R&D center in Waltham, Massachusetts; a research and manufacturing facility in Athlone, Ireland; and a manufacturing facility in Wilmington, Ohio. For more information, please visit Alkermes' website at [www.alkermes.com](http://www.alkermes.com).

#### **Note Regarding Forward-Looking Statements**

Certain statements set forth in this press release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, but not limited to, statements concerning: review and potential approval by the FDA of the ALKS 5461 NDA and the anticipated timing of such review and approval; and the potential therapeutic and commercial value of ALKS 5461. You are cautioned that forward-looking statements are inherently uncertain. Although the company believes that such statements are based on reasonable assumptions within the bounds of its knowledge of its business and operations, the forward-looking statements are neither promises nor guarantees and they are necessarily subject to a high degree of uncertainty and risk. Actual performance and results may differ materially from those expressed or implied in the forward-looking statements due to various risks and uncertainties. These risks and uncertainties include, among others: whether the preclinical and clinical results of ALKS 5461 studies will meet the regulatory requirements for approval by the FDA; whether the FDA's bases for the Refusal to File letter for the ALKS 5461 NDA, later rescinded by the FDA, or other bases will cause the FDA to require more data or information prior to approval of ALKS 5461; whether ALKS 5461 will be approved by the FDA in a timely manner or at all; and those risks and uncertainties described under the heading "Risk Factors" in the company's Annual Report on Form 10-K for the year ended Dec. 31, 2017 and in subsequent filings made by the company with the U.S. Securities and Exchange Commission (SEC), which are available on the SEC's website at [www.sec.gov](http://www.sec.gov). Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Except as required by law, the company disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release.

*DSM-5®* is a registered trademark of the American Psychiatric Association.

<sup>1</sup> National Institutes of Mental Health: Major Depression. Accessed on Oct. 31, 2018 from <https://www.nimh.nih.gov/health/statistics/major-depression.shtml>.

<sup>2</sup> Rush AJ et al (2007) *Am J. Psychiatry*, 163:11, pp. 1905-1917 (STAR\*D Study).

#### **Alkermes Contacts:**

For Investors: Eva Stroynowski, +1 781 609 6823  
Sandy Coombs, +1 781 609 6377  
For Media: Sherry Feldberg, +1 781 609 6276



 View original content to download multimedia:<http://www.prnewswire.com/news-releases/trading-in-alkermes-ordinary-shares-halted-today-300741631.html>

SOURCE Alkermes plc